Determinants of Willingness to Pay for a New Therapy in a Sample of Menopausal-Aged Women

Rasch A, Hodek J-M, Runge C, Greiner W (2009)
PHARMACOECONOMICS 27(8): 693-704.

Journal Article | Published | English

No fulltext has been uploaded

Author
; ; ;
Abstract
Background: Menopause is a natural physiological event that usually begins in women between the ages of 48 and 55 years. In many cases, this event is associated with unpleasant somatic-vegetative, urogenital or psychological symptoms. Objective: To test the health and social demographic factors (especially household income level) that influence willingness to pay (WTP) for a new hormone-free treatment in women of menopausal age. Methods: 1365 women between the ages of 45 and 73 years were surveyed about their health and WTP for the new treatment. WTP was evaluated with a closed-ended binary questionnaire (four groups with different levels of co-payment between is an element of 15 and is an element of 60), using the contingent valuation method. The average WTP was calculated according to the area under the demand function. Factors contributing to payment readiness were examined by means of binary logistic regression. Results: WTP was significantly affected by women's opinion of the new medication, the level of co-payment required, net household income, whether currently in treatment for menopausal symptoms, and Menopause Rating Scale (MRS) values. Compared with other factors, the level of co-payment was predicted to have a negative impact on WTP. Income level is an important factor in WTP and correlates highly with several other health-related variables (WHO-5 index, MRS value, receipt of other menopause medicines and existing co-morbidity). The average co-payment that our group of women was willing to pay was between is an element of 17 and is an element of 35 per month, or is an element of 24 to is an element of 42 for women who were currently receiving treatment for symptorns of menopause. While interpreting the results, it should be considered that the hypothetical therapy was assumed to be a new non-reimbursable alternative to conventional therapy offered under the existing statutory framework for health insurance in Germany. Conclusions: Despite some methodological limitations, these results are useful for examining the factors affecting WTP and incremental utilities for future medicine dealing with menopause.
Publishing Year
ISSN
PUB-ID

Cite this

Rasch A, Hodek J-M, Runge C, Greiner W. Determinants of Willingness to Pay for a New Therapy in a Sample of Menopausal-Aged Women. PHARMACOECONOMICS. 2009;27(8):693-704.
Rasch, A., Hodek, J. - M., Runge, C., & Greiner, W. (2009). Determinants of Willingness to Pay for a New Therapy in a Sample of Menopausal-Aged Women. PHARMACOECONOMICS, 27(8), 693-704.
Rasch, A., Hodek, J. - M., Runge, C., and Greiner, W. (2009). Determinants of Willingness to Pay for a New Therapy in a Sample of Menopausal-Aged Women. PHARMACOECONOMICS 27, 693-704.
Rasch, A., et al., 2009. Determinants of Willingness to Pay for a New Therapy in a Sample of Menopausal-Aged Women. PHARMACOECONOMICS, 27(8), p 693-704.
A. Rasch, et al., “Determinants of Willingness to Pay for a New Therapy in a Sample of Menopausal-Aged Women”, PHARMACOECONOMICS, vol. 27, 2009, pp. 693-704.
Rasch, A., Hodek, J.-M., Runge, C., Greiner, W.: Determinants of Willingness to Pay for a New Therapy in a Sample of Menopausal-Aged Women. PHARMACOECONOMICS. 27, 693-704 (2009).
Rasch, Andrej, Hodek, Jan-Marc, Runge, Claus, and Greiner, Wolfgang. “Determinants of Willingness to Pay for a New Therapy in a Sample of Menopausal-Aged Women”. PHARMACOECONOMICS 27.8 (2009): 693-704.
This data publication is cited in the following publications:
This publication cites the following data publications:

2 Citations in Europe PMC

Data provided by Europe PubMed Central.

Women's preferences toward attributes of local estrogen therapy for the treatment of vaginal atrophy.
Mattsson LA, Ericsson A, Bogelund M, Maamari R., Maturitas 74(3), 2013
PMID: 23312488
Willingness to pay for hospice care using the contingent valuation method.
Kim MO, Lee KS, Kim JH, Joo JS., Yonsei Med. J. 52(3), 2011
PMID: 21488196

44 References

Data provided by Europe PubMed Central.


Eberhardt, GMS Health Technol Assess 3(Doc03), 2007
Managing the menopause.
Roberts H., BMJ 334(7596), 2007
PMID: 17413174

Rote, 2008

Potthoff, German Medical Science 02(Doc05), 2004
The Menopause Rating Scale (MRS) scale: a methodological review.
Heinemann K, Ruebig A, Potthoff P, Schneider HP, Strelow F, Heinemann LA, Do MT., Health Qual Life Outcomes 2(), 2004
PMID: 15345062
The Menopause Rating Scale (MRS) as outcome measure for hormone treatment? A validation study.
Heinemann LA, DoMinh T, Strelow F, Gerbsch S, Schnitker J, Schneider HP., Health Qual Life Outcomes 2(), 2004
PMID: 15555079
The Menopause Rating Scale (MRS): comparison with Kupperman index and quality-of-life scale SF-36.
Schneider HP, Heinemann LA, Rosemeier HP, Potthoff P, Behre HM., Climacteric 3(1), 2000
PMID: 11910610
Validity of the five-item WHO Well-Being Index (WHO-5) in an elderly population.
Bonsignore M, Barkow K, Jessen F, Heun R., Eur Arch Psychiatry Clin Neurosci 251 Suppl 2(), 2001
PMID: 11824831

Donaldson, Appl Econ 30(), 1998

Field, 2005
The impact of hormone replacement therapy on quality of life and willingness to pay.
Zethraeus N, Johannesson M, Henriksson P, Strand RT., Br J Obstet Gynaecol 104(10), 1997
PMID: 9332999
Willingness to pay for hormone replacement therapy.
Zethraeus N., Health Econ 7(1), 1998
PMID: 9541082
Willingness to pay for antihypertensive care: evidence from a staff-model HMO.
Ramsey SD, Sullivan SD, Psaty BM, Patrick DL., Soc Sci Med 44(12), 1997
PMID: 9194252
Age at menopause as a risk factor for cardiovascular mortality.
van der Schouw YT, van der Graaf Y, Steyerberg EW, Eijkemans JC, Banga JD., Lancet 347(9003), 1996
PMID: 8602000

Export

0 Marked Publications

Open Data PUB

Web of Science

View record in Web of Science®

Sources

PMID: 19712011
PubMed | Europe PMC

Search this title in

Google Scholar